帕萨妥珠单抗
化合物
帕萨妥珠单抗（INN：parsatuzumab[1]；开发代号：MEGF0444A）是一种人源化单克隆抗体，设计用于治疗多种癌症，包括转移性结直肠癌和非鳞状非小细胞肺癌。它充当免疫调节剂并与EGFL7结合。[2][3]
| 单克隆抗体 | |
|---|---|
| 种类 | 完整抗体 |
| 目标 | EGFL7 |
| 临床资料 | |
| ATC码 |
|
| 识别信息 | |
| CAS号 | 1312797-14-0 |
| ChemSpider |
|
| UNII | |
| 化学信息 | |
| 化学式 | C6560H10130N1758O2046S46 |
| 摩尔质量 | 147,836.22 g·mol−1 |
参考资料
编辑- ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107 (PDF). WHO Drug Information. 2012, 26 (2) [2024-03-19]. （原始内容存档 (PDF)于2016-03-04）.
- ^ García‐Carbonero, Rocío; van Cutsem, Eric; Rivera, Fernando; Jassem, Jacek; Gore, Ira; Tebbutt, Niall; Braiteh, Fadi; Argiles, Guillem; Wainberg, Zev A.; Funke, Roel; Anderson, Maria. Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer. The Oncologist. 2017-04, 22 (4) [2024-03-19]. ISSN 1083-7159. PMC 5388369
. PMID 28275117. doi:10.1634/theoncologist.2016-0133. （原始内容存档于2024-04-22）.
- ^ von Pawel, Joachim; Spigel, David R.; Ervin, Thomas; Losonczy, György; Barlesi, Fabrice; Juhász, Erzsébet; Anderson, Maria; McCall, Bruce; Wakshull, Eric; Hegde, Priti; Ye, Weilan. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer. The Oncologist. 2018-06-01, 23 (6) [2024-03-19]. ISSN 1083-7159. PMC 6067939 . PMID 29438092. doi:10.1634/theoncologist.2017-0690. （原始内容存档于2024-04-20） （英语）.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Parsatuzumab, American Medical Association.
